Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/3/2008

der (with or without cardiovascular risk factor) or above 70 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40%). Patients were randomized to receive Multaq(R) 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of Multaq(R) on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalization for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoint was conducted in order to confirm the consistent benefit of Multaq in atrial fibrillation or atrial flutter patients in reducing major cardiovascular complications like stroke, which is a leading cause of cardiovascular hospitalization or death in this patient population.

About Multaq(R) (dronedarone)

Multaq(R) is an investigational treatment and the only anti-arrhythmic drug (AAD) to have shown a significant reduction in morbidity and mortality in atrial fibrillation /atrial flutter patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity. Multaq(R), discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 7,000 patients. Multaq(R) is one of the major therapeutic innovations for atrial fibrillation in the last twenty years.

Mult
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
5. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Arpida Provides Further Comments on the Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Decision Resources Group finds that ... for biologic therapy, only a proportion of ... cite patients, discomfort with biological therapy as ... followed by cost-related issues and payer restrictions. ... Janssen Biotech,s Remicade and AbbVie,s Humira are ...
(Date:9/17/2014)... and SAN JOSE, Calif. , ... has been named as a laureate of The Tech Awards ... applying technology to benefit humanity and spark global change. The ... Innovation, and presented by Applied Materials, Inc., selected Gradian as ... Photo - http://photos.prnewswire.com/prnh/20140917/146680 ...
(Date:9/17/2014)... , Sept. 17, 2014  Lightbeam Health Solutions ... Care Organization (Physician Direct ACO) to deploy the ... in providing better care while reducing costs. ... Physician Direct Accountable Care Organization is the ... (OPNS). The OPNS mission is to be the ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3
... Oct. 13 Allscripts (Nasdaq: ... financial results for the three and nine months ended ... on Monday, November 8, 2010. Allscripts management will host ... earnings and other information at 4:30 PM Eastern Standard ...
... (Nasdaq: STXS ) announced today that the new ... of 2010.  The Company generated new capital orders of $12.2 ... placed during the third quarter of 2009, and a 19% ... the Company,s Niobe® Remote Magnetic Navigation System totaled $8.1 million, ...
Cached Medicine Technology:Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 2Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 3Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year 2Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year 3Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year 4
(Date:9/17/2014)... 2014 People who struggle to distinguish between ... http://www.perwickstrom.com and get the answer by reading Per ... out, is that a business plan and a business strategy ... commented Per Wickstrom. “The way I view it is that ... strategy which is part two.” , According to the ...
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... News) -- Positive messages about the health benefits of ... a new study suggests. Although smokers who think ... about the harmful effects of smoking, researchers found smokers ... more from "gain-framed," or positive, messages about how quitting ... using a mix of both types of messages might ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... Washingtonian ... ... was identified as a "Top Therapist" in the July 2009 issue of Washingtonian ... playing in the Washington, DC, area for more than four decades thanks to features like ...
... ... supplier of industrial and technical parts and free CAD images to engineers, ... customers. John Carrier, the company,s President, says the new ReidSupply.com is all about ... on marketing. The new site takes the customer exactly where they want to ...
... LONDON, July 7 Frost & Sullivan has conferred ... (VWS). The "2008 Frost & Sullivan European Pharmaceutical Water ... VWS for its successful strategies that have enabled it ... process water and wastewater solution providers for the pharmaceutical ...
... OAK BROOK, Ill. (July 7, 2009) Using magnetic resonance ... and accurately locate lesions prior to surgery, according to a ... . "Pelvic MRI at 3 Tesla is a ... said the study,s lead author, Nathalie Hottat, M.D., from the ...
... SMOKING CESSATION MAY PROVIDE IMMEDIATE BENEFIT TO HEART ... provides immediate benefits to patients. Researchers from the ... examined specific inflammatory biomarkers associated with cardiovascular disease ... cessation process. Results showed that smoking cessation resulted ...
... Sonitus Medical, Inc., a medical device company developing the ... sound via the teeth, today announced the acceptance for ... SoundBite(TM) hearing system. The article, featuring a preliminary evaluation ... in an upcoming issue of the esteemed Otology ...
Cached Medicine News:Health News:Karen J. Osterle Recognized as a Top Psychotherapist in Washingtonian Magazine 2Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 2Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 3Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 4Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 5Health News:MRI accurately depicts deep endometriosis 2Health News:News briefs from the July issue of CHEST 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 3
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Inquire...
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: